Responses to Ixekizumab in Male and Female Patients with Psoriatic Arthritis: Results from Two Randomized, Phase 3 Clinical Trials
ConclusionCompared to female patients, male patients had greater response rates in ACR20/50/70, MDA/VLDA, and DAPSA LDA/remission and numerically larger improvements in these measures ’ individual components, although clinical significance is unclear. Continued efforts to understand sex differences in treatment response may provide insights that can help optimize clinical decision making.Trial registrationClinicalTrials.gov identifiers, NCT01695239 and NCT02349295. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - April 9, 2022 Category: Rheumatology Source Type: research
Photobiomodulation Therapy: A New Light in the Treatment of Systemic Sclerosis Skin Ulcers
ConclusionsThe positive clinical results and the absence of side effects suggest that EmoLED® could be a promising tool in the management of SSc-SU, with an interesting role to play in the healing process in addition to conventional systemic and local treatments. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - March 25, 2022 Category: Rheumatology Source Type: research
Analysis of the Pharmacoutilization of Biological Drugs in Psoriatic Arthritis Patients: A Real-World Retrospective Study Among an Italian Population
ConclusionsThis real-world study of PsA pharmacoutilization in Italy showed that more than one-third of patients were systemically untreated, and almost 20% were receiving biological medications. Among biological users, increasing use of IL-inhibitors and a decrease in TNF-inhibitors prescriptions over the years were found. A rather-high extent of persistency in treatment was observed. A focused analysis on IXE patients revealed over half of them to be bio-na ïve, while around one-fourth were bio-experienced to IL inhibitors. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - March 22, 2022 Category: Rheumatology Source Type: research
An Observational Retrospective Matched Cohort Study of Healthcare Resource Utilisation and Costs in UK Patients with Moderate to Severe Osteoarthritis Pain
ConclusionIn the population of Salford, UK, patients with M-S OA pain had significantly higher annual HCRU and costs compared with matched controls without OA; generally, these were even higher in patients with severe OA pain. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - March 21, 2022 Category: Rheumatology Source Type: research
Effect of Secukinumab on Traditional Cardiovascular Risk Factors and Inflammatory Biomarkers: Post Hoc Analyses of Pooled Data Across Three Indications
ConclusionsSecukinumab led to a rapid and sustained reduction in hsCRP and the NLR in patients with IMIDs with a high systemic inflammatory burden. Traditional CV risk factors remained stable for at least 1 year in patients with psoriasis, PsA, and axSpA. Taken together, secukinumab had a favorable effect on systemic inflammation without impact on traditional CV risk factors.Trials RegistrationClinicalTrials.gov, NCT01365455, NCT01358578, NCT01406938, NCT01555125, NCT01636687, NCT02752776, NCT02074982, NCT02826603, NCT01752634, NCT01989468, NCT02294227, NCT02404350, NCT02745080, NCT01863732, NCT01649375, NCT02008916, NCT...
Source: Rheumatology and Therapy - March 19, 2022 Category: Rheumatology Source Type: research
Usability Study of PF-06410293, an Adalimumab Biosimilar, by Prefilled Pen: Open-Label, Single-Arm, Sub-Study of a Phase 3 Trial in Patients with Rheumatoid Arthritis
ConclusionsAll actual PFP users could safely and effectively administer ADL-PF by PFP at each visit, and nearly all participants who completed the sub-study elected to continue study treatment using PFP injections.Trial registrationClinicalTrials.gov identifier: NCT02480153; EudraCT number: 2014-000352-29. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - March 18, 2022 Category: Rheumatology Source Type: research
Patient Perception of Medical Care for Psoriatic Arthritis in North America and Europe: Results from a Global Patient Survey
ConclusionsAlthough perception of overall health and disease severity varied, many patients from both regions still experienced symptoms despite receiving medications for PsA, wished they had greater choice of medications, and/or would like to change an aspect of their medications. While these survey findings are subject to selection bias, they do indicate there is scope to improve the treatment of PsA. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - March 17, 2022 Category: Rheumatology Source Type: research
Experiences and Treatment Preferences in Patients With Psoriatic Arthritis: A Cross-Sectional Study in the ArthritisPower Registry
ConclusionsPatients with PsA from a rheumatology registry found musculoskeletal pain symptoms to be the most bothersome and prioritized improvements to functional impacts of their disease. These findings can better inform development of new therapies and guide shared patient-provider treatment decision-making. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - March 13, 2022 Category: Rheumatology Source Type: research
Evaluation of Serious Infection in Pediatric Patients with Low Immunoglobulin Levels Receiving Rituximab for Granulomatosis with Polyangiitis or Microscopic Polyangiitis
ConclusionsThe majority of pediatric patients who received rituximab for GPA/MPA with prolonged low immunoglobulin levels did not experience SIs. In patients with SIs, these events were manageable, and the number of SIs did not increase over time or with multiple rituximab treatments. These observations are consistent with the rituximab safety profile in adults with GPA/MPA.Trial registrationClinicalTrials.gov identifier, NCT01750697. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - March 12, 2022 Category: Rheumatology Source Type: research
Responding to and Driving Change in Rheumatology: Report from the 12th International Immunology Summit 2021
AbstractThe coronavirus disease 2019 (COVID-19) pandemic has accelerated changes to rheumatology daily clinical practice. The main goal of the 12th International Immunology Summit, held 25 –26 June, 2021 (virtual meeting), was to provide direction for these active changes rather than undergoing change reactively in order to improve patient outcomes. This review describes and explores the concept of change in rheumatology clinical practice based on presentations from the Immunology S ummit. Many of the changes to rheumatology practice brought about by the COVID-19 pandemic may be considered as having a positive impact on ...
Source: Rheumatology and Therapy - March 12, 2022 Category: Rheumatology Source Type: research
A Randomised Controlled Trial Comparing the Pharmacokinetics and Tolerability of the Proposed Adalimumab Biosimilar MSB11022 Delivered via Autoinjector and Pre-filled Syringe in Healthy Subjects
ConclusionDelivery of MSB11022 via an AI is bioequivalent to delivery via a PFS. The safety and tolerability profile of MSB11022 was comparable across administration methods. The development of an AI for MSB11022 provides a choice of self-injection devices available to patients, potentially improving treatment compliance.Trial RegistrationClinicalTrials.gov trial identifier: NCT04018599. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - March 9, 2022 Category: Rheumatology Source Type: research
A Randomized, Open-Label, Single-Dose Study to Assess Safety and Systemic Exposure of Triamcinolone Acetonide Extended-Release in Patients With Hip Osteoarthritis
ConclusionsFollowing a single IA injection in the hip, TA-ER was generally well tolerated, with a safety profile comparable to that of TAcs. Systemic TA exposure was markedly lower in TA-ER-treated patients, consistent with the PK profile observed in knee osteoarthritis.Clinicaltrials.gov identifier: NCT03382262. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - March 8, 2022 Category: Rheumatology Source Type: research
Employment, Work Productivity, and Biologic Treatments in Self-Reported Axial Spondyloarthritis: a Cross-Sectional Study in a Female Predominant Population from the ArthritisPower Registry
ConclusionsAlthough bDMARD treatment rates were similar between employed and not employed participants, disease activity and overall health were better in employed than non-employed participants. Employed participants experienced substantial work productivity impairment due to axSpA. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - February 21, 2022 Category: Rheumatology Source Type: research
Post Hoc Analysis of Predictors of Clinical Response to Repository Corticotropin Injection in Persistently Active Rheumatoid Arthritis
ConclusionsThese results identify specific patient characteristics that may be considered predictors of positive or negative clinical response to RCI. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - February 20, 2022 Category: Rheumatology Source Type: research
The Role of Shared Epitope in Rheumatoid Arthritis Prognosis in Relation to Anti-Citrullinated Protein Antibody Positivity
ConclusionsSE is strongly associated with ACPA positivity and higher disease activity in patients with RA. SE was associated with greater increases in disease activity over 1 year, which was partially mediated by the presence of ACPA.Trial RegistrationClinicalTrials.gov identifier: NCT01793103; registration date: February 15, 2013, retrospectively registered. (Source: Rheumatology and Therapy)
Source: Rheumatology and Therapy - February 16, 2022 Category: Rheumatology Source Type: research
